Report
BioNTech SE : Strong Q3, FY guidance raised, but we had hoped for more
>Q3 stronger than expected, FY guidance raised - Q3 revenues came in at € 6.09bn vs c.€ 5.7bn our estimate and c.€ 5.9bn or the consensus (FactSet). EBIT was € 4.72bn (margin of 77.6%) beating our estimate by 3% and the consensus by 4%; 2) FY guidance has been raised (the group issues guidance for sales and opex – no change to opex guidance) from sales of € 15.9bn to € 16-17bn (€ 2.2bn was set on an order book at 21 July, now guidance is based on up to € 2.5bn of dose...
Underlying
BioNTech SE
Provider
Oddo BHF
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Martial Descoutures
Other Reports on these Companies
Other Reports from Oddo BHF
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.